PepGen (PEPG) Accounts Payables (2021 - 2026)
PepGen (PEPG) posted Accounts Payables of $622000.0 for Q1 2026, down 24.33% sequentially from $822000.0 in Q4 2025, and down 76.95% YoY from $2.7 million in Q1 2025.
Analysis
PepGen (PEPG) Accounts Payables (2021 - 2026) Analysis & Trends
PepGen has reported Accounts Payables for 6 years, with the latest figure at $622000.0 in Q1 2026.
- Quarterly Accounts Payables fell 76.95% year-over-year to $622000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $622000.0 (down 76.95% YoY) and the FY2025 annual result came in at $822000.0, down 53.08% from the prior year.
- Accounts Payables retreated to $622000.0 in Q1 2026 per PEPG's latest filing, from $822000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $7.7 million in Q2 2024 and troughed at $622000.0 in Q1 2026.
- A 5-year average of $2.6 million and a median of $1.8 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables jumped 326.5% in 2024, then slumped 88.94% in 2025.
- Over 5 years, Accounts Payables stood at $1.4 million in 2022, then dropped by 26.21% to $1.0 million in 2023, then soared by 74.33% to $1.8 million in 2024, then slumped by 53.08% to $822000.0 in 2025, then decreased by 24.33% to $622000.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $622000.0, $822000.0, and $766000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 1.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Mn |
| Mar 31, 2026 | 622,000.00 |
| Dec 31, 2025 | 822,000.00 |
| Sep 30, 2025 | 766,000.00 |
| Jun 30, 2025 | 856,000.00 |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 5.93 Mn |
| Jun 30, 2024 | 7.74 Mn |
| Mar 31, 2024 | 1.48 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 1.36 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 5.39 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Dec 31, 2021 | 3.24 Mn |